MX2022010410A - Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2. - Google Patents

Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2.

Info

Publication number
MX2022010410A
MX2022010410A MX2022010410A MX2022010410A MX2022010410A MX 2022010410 A MX2022010410 A MX 2022010410A MX 2022010410 A MX2022010410 A MX 2022010410A MX 2022010410 A MX2022010410 A MX 2022010410A MX 2022010410 A MX2022010410 A MX 2022010410A
Authority
MX
Mexico
Prior art keywords
solid
surfactant
polymeric carrier
compound
hot melt
Prior art date
Application number
MX2022010410A
Other languages
English (en)
Inventor
Yi Chen
Original Assignee
Guangzhou Lupeng Pharmaceutical Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Lupeng Pharmaceutical Company Ltd filed Critical Guangzhou Lupeng Pharmaceutical Company Ltd
Publication of MX2022010410A publication Critical patent/MX2022010410A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Una dispersión del sólido proapoptótica comprende un compuesto inhibidor de la familia de proteínas Bcl-2 de Fórmula (A) tal y como se define por el presente, dispersado en una matriz sólida que comprende (a) un substrato portador polimérico soluble en agua farmacológicamente aceptable y (b) un tensioactivo farmacológicamente aceptable; un proceso para preparar dicha dispersión de sólidos implica someter a una temperatura elevada el compuesto de Fórmula (A), el substrato portador polimérico soluble en agua y el tensioactivo para proporcionar una mezcla semisólida que pueda extruirse; y la refrigeración de la extrusión resultante para proporcionar una matriz sólida que comprenda el substrato portador polimérico y el tensioactivo con el compuesto dispersado en la misma en una forma esencialmente no cristalina; la dispersión de sólidos es adecuada para la administración oral a un sujeto que necesite un tratamiento para una enfermedad caracterizada por la sobreexpresión de una o más proteínas antiapoptóticas de la familia Bcl-2, por ejemplo un cáncer o una enfermedad autoinmune o inmune.
MX2022010410A 2020-02-24 2021-02-23 Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2. MX2022010410A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062980700P 2020-02-24 2020-02-24
US202063053565P 2020-07-17 2020-07-17
PCT/US2021/019181 WO2021173523A1 (en) 2020-02-24 2021-02-23 Hot melt extruded solid dispersions containing a bcl2 inhibitor

Publications (1)

Publication Number Publication Date
MX2022010410A true MX2022010410A (es) 2022-12-07

Family

ID=74875347

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010410A MX2022010410A (es) 2020-02-24 2021-02-23 Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2.

Country Status (10)

Country Link
US (1) US20230295183A1 (es)
EP (1) EP4110298A1 (es)
JP (1) JP2023514750A (es)
KR (1) KR20220158725A (es)
CN (1) CN115484933A (es)
AU (1) AU2021228622A1 (es)
CA (1) CA3173041A1 (es)
IL (1) IL295803A (es)
MX (1) MX2022010410A (es)
WO (1) WO2021173523A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023104043A1 (zh) 2021-12-06 2023-06-15 杭州和正医药有限公司 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用
US11964990B2 (en) 2022-01-21 2024-04-23 Abbvie Inc. 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors
CN115894495B (zh) * 2022-11-29 2024-08-09 大连理工大学 一种基于尿酸与苯硼酸衍生物复合晶体的纯有机室温磷光材料的制备方法
CN116270660A (zh) * 2023-03-30 2023-06-23 广州麓鹏制药有限公司 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用
CN116236583A (zh) * 2023-03-30 2023-06-09 广州麓鹏制药有限公司 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
NZ601350A (en) 2007-11-16 2013-08-30 Abbvie Inc Method of treating arthritis
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2811805A1 (en) * 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
US10231929B2 (en) * 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion
WO2017132474A1 (en) * 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
EP3333167A1 (en) * 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
MX2020002033A (es) 2017-08-23 2020-08-20 Guangzhou Lupeng Pharmaceutical Company Ltd Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas.
WO2020041405A1 (en) * 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors

Also Published As

Publication number Publication date
JP2023514750A (ja) 2023-04-07
CA3173041A1 (en) 2021-09-02
US20230295183A1 (en) 2023-09-21
CN115484933A (zh) 2022-12-16
AU2021228622A1 (en) 2022-10-13
EP4110298A1 (en) 2023-01-04
KR20220158725A (ko) 2022-12-01
WO2021173523A1 (en) 2021-09-02
IL295803A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
MX2022010410A (es) Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2.
EP4218731A3 (en) Melt-extruded solid dispersions containing an apoptosis-inducing agent
Leite-de-Moraes et al. Fas/Fas ligand interactions promote activation-induced cell death of NK T lymphocytes
Zhan et al. Gut microbiota protects against gastrointestinal tumorigenesis caused by epithelial injury
Bogdan et al. Production of interferon-γ by myeloid cells–fact or fancy?
Radojcic et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination
Hershko et al. Mast cell and T cell communication; amplification and control of adaptive immunity
JP2019073550A (ja) 炎症の治療のための免疫修飾粒子
MX349533B (es) Dispersiones solidas que contienen un agente inductor de apoptosis.
JP2010500411A5 (es)
MX2008009970A (es) Conjugados de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciosos.
NZ530950A (en) 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
Diao et al. Adjuvant and immunostimulatory effects of LPS and β-glucan on immune response in Japanese flounder, Paralichthys olivaceus
JP7086077B2 (ja) 局所領域的腫瘍治療後の免疫調節
Moss et al. Identification of phagocytic cells, NK-like cytotoxic cell activity and the production of cellular exudates in the coelomic cavity of adult zebrafish
JP2019518740A (ja) 可塑剤としてのアミノ糖の使用
JP7109535B2 (ja) キサントフモールベースの組成物
US20160113966A1 (en) Composition and methods of culture supernatant of khyg-1 cells
HU206180B (en) Process for producing pharmaceutical compositions with long effect and comprising macrolide
Wleklik et al. Tuftsin induced tumor necrosis activity
CN118186047A (zh) 免疫治疗剂的剂量确定
Bhowmik et al. Innate immune-inflammatory signaling milieu in myeloid leukemia and aging-associated clonal hematopoiesis pathologies
Griggs et al. Treatment of refractory undifferentiated acute myelogenous leukemia with all‐trans‐retinoic acid
Salami et al. The effect of equine bone marrow‐derived mesenchymal stem cells on the expression of apoptotic genes in neutrophils
CN113905764A (zh) 用于治疗癌症的前体半胱天冬酶-3活化作用和免疫疗法